Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2

2(50.0%)

Phase 3

1(25.0%)

Phase 4

1(25.0%)

4Total

Phase 2(2)

Phase 3(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT03935217Phase 3Completed

A Phase 3 Study of Solosec® for the Treatment of Trichomoniasis

Role: lead

NCT05360550Phase 2Completed

A Study to Evaluate the Effect of a Contraceptive Vaginal Ring LSP- 5415 on Ovarian Function in Healthy Adult Females

Role: lead

NCT05360576Phase 2Completed

An Open-label, Randomized, 2-Period, Crossover, Pharmacokinetics Study

Role: lead

NCT03937869Phase 4Completed

Evaluate the Safety of a Single Oral Dose of Solosec™ (Secnidazole) 2g for the Treatment of Adolescent Girls With BV

Role: lead

All 4 trials loaded